Abstract
A structurally novel set of inhibitors of bacterial type II topoisomerases with potent in vitro and in vivo antibacterial activity was developed. Dual-targeting ability, hERG inhibition, and pharmacokinetic properties were also assessed.
Copyright © 2013. Published by Elsevier Ltd.
MeSH terms
-
Animals
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / chemistry
-
Anti-Bacterial Agents / pharmacology*
-
DNA Gyrase / metabolism
-
DNA Topoisomerase IV / antagonists & inhibitors*
-
DNA Topoisomerase IV / metabolism
-
DNA Topoisomerases, Type II / metabolism
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Ether-A-Go-Go Potassium Channels / antagonists & inhibitors
-
Humans
-
Microbial Sensitivity Tests
-
Molecular Structure
-
Quinolines / administration & dosage
-
Quinolines / chemistry
-
Quinolines / pharmacology*
-
Rats
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / enzymology
-
Streptococcus pneumoniae / drug effects*
-
Streptococcus pneumoniae / enzymology
-
Structure-Activity Relationship
-
Topoisomerase II Inhibitors*
Substances
-
Anti-Bacterial Agents
-
Enzyme Inhibitors
-
Ether-A-Go-Go Potassium Channels
-
Quinolines
-
Topoisomerase II Inhibitors
-
quinoline
-
DNA Topoisomerase IV
-
DNA Gyrase
-
DNA Topoisomerases, Type II